Silence Therapeutics (NASDAQ:SLN – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Silence Therapeutics to similar companies based on the strength of its institutional ownership, risk, valuation, earnings, dividends, analyst recommendations and profitability.
Profitability
This table compares Silence Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silence Therapeutics | -8,943.86% | -56.32% | -32.42% |
| Silence Therapeutics Competitors | -12,516.26% | -215.37% | -31.41% |
Analyst Ratings
This is a breakdown of recent ratings for Silence Therapeutics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silence Therapeutics | 1 | 4 | 2 | 0 | 2.14 |
| Silence Therapeutics Competitors | 9920 | 15335 | 45741 | 1601 | 2.54 |
Silence Therapeutics presently has a consensus price target of $24.00, indicating a potential upside of 21.15%. As a group, “Biotechnology” companies have a potential upside of 110.28%. Given Silence Therapeutics’ peers stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics has less favorable growth aspects than its peers.
Institutional and Insider Ownership
98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Risk and Volatility
Silence Therapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Silence Therapeutics’ peers have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.
Valuation and Earnings
This table compares Silence Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Silence Therapeutics | $560,000.00 | -$88.61 million | -18.51 |
| Silence Therapeutics Competitors | $690.26 million | $7.76 million | -18.38 |
Silence Therapeutics’ peers have higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
Silence Therapeutics peers beat Silence Therapeutics on 9 of the 13 factors compared.
Silence Therapeutics Company Profile
Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
